Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Chugai Obtains Approval of First Dual-Function Gene Panel Test
Chugai Pharmaceutical said on December 27 that it has gained approval for “FoundationOne CDx Cancer Genomics Profile” for use in gene mutation analysis programs for solid tumors and somatic cells. This is the first approval for a gene panel test with…
To read the full story
Related Article
- Chuikyo Approves Coverage for Chugai’s FoundationOne as Companion Diagnostic for Lynparza
December 16, 2019
- Chuikyo Agrees to Require Genetic Info Submission for Insurance Coverage of Cancer Genomic Panel Tests
April 25, 2019
- Chugai Files for Gene Test for Companion Diagnostic to Lynparza
April 1, 2019
- Chugai, SRL Link Up for Cancer Gene Mutation Tests
March 22, 2019
- First Cancer Gene Panel Test Approved in Japan: Sysmex
December 27, 2018
BUSINESS
- FDA Extends Review of Capricor’s DMD Cell Therapy by 3 Months
August 26, 2026
- Leqembi Iqlik Now Available for Alzheimer’s Initiation Use in US
August 25, 2026
- FDA Puts Regenxbio’s MPS II Gene Therapy Back on Clinical Hold
August 25, 2026
- Toho Builds Alternative Drug Delivery Options for Disaster Readiness
August 25, 2026
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…